Novartis Pharma AG — Sponsor Intelligence | 224 EU Trials

Filter these 224 trials by condition, phase, country and more.

Open in Search →

224 Registered trials

70 Recruiting

133 Completed trials

26 Countries active

253 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 87 Phase II/III: 2 Phase II: 56 Phase I/II: 19 Phase III/IV: 2 Phase IV: 12 Phase I: 17 Phase I (Other): 18 Phase I (FiH): 11

Oversight events:

2 serious breaches 129 temporary halts 1 urgent safety measure 23 unexpected events 10 corrective measures across 53 trials

View oversight register →

100%

133 of 133 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 16 Systemic lupus erythematosus 7 Colorectal cancer 6 Sjogren's syndrome 5 Lupus nephritis 5 Chronic spontaneous urticaria 5 Relapsing multiple sclerosis 4 IgA nephropathy 4 Multiple sclerosis relapse 4 Hormone receptor positive HER2 negative breast cancer 4 Triple negative breast cancer 4 Giant cell arteritis 3

Top IMPs

IANALUMAB 16 REMIBRUTINIB 14 IPTACOPAN 13 LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN 9 RAPCABTAGENE AUTOLEUCEL 9 GOZETOTIDE 7 PELACARSEN 6 RIBOCICLIB 6 ASCIMINIB HYDROCHLORIDE 5 IPTACOPAN HYDROCHLORIDE 5 1-{6-[(4M)-4-(5-CHLORO-6-METHYL-1H -INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H -INDAZOL-5-YL)-1H -PYRAZOL-1-YL]-2-AZASPIRO[3.3]HEPTAN-2-YL}PROP-2-EN-1-ONE 4 ALPELISIB 4

All trials — page 6

224 total

An open-label study to assess safety, efficacy and cellular kinetics of YTB323 in severe, refractory systemic lupus erythematosus (srSLE). Ended

2023-510081-27-00 Phase I/II 3 countries RAPCABTAGENE AUTOLEUCEL
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants Ended

2024-514004-14-00 Phase I (Other) 4 countries
Roll-over study for patients who have completed a prior Novartis sponsored sabatolimab (MBG453) study and are judged by the investigator to … Ended

2024-515281-14-00 Phase II 6 countries SABATOLIMAB
Phase 3 study to evaluate two regimens of ianalumab on top of standardof- care therapy in patients with systemic lupus erythematosus (SIRIUS… Ended

2023-508498-97-00 Phase III 7 countries IANALUMAB
An extension study of long-term efficacy, safety and tolerability of remibrutinib in chronic spontaneous urticaria patients who completed pr… Ended

2024-510818-33-00 Phase III 10 countries REMIBRUTINIB
Long-term follow-up of patients with spinal muscular atrophy Treated with OAV101 IT or OAV101 IV in Clinical Trials Ended

2024-511707-42-00 Phase III 6 countries ONASEMNOGENE ABEPARVOVEC
Study to evaluate the long-term safety of GT005 in participants having macular degeneration that led to geographic atrophy in their eyes and… Ended

2024-510946-15-00 Phase I/II 4 countries GT005
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With N… Ended

2024-510947-71-00 Phase III 10 countries
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic P… Ended

2024-511126-31-00 Phase III 6 countries
Three-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Ended

2024-511068-10-00 Phase III 11 countries IANALUMAB
A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsore… Ended

2024-514891-41-00 Phase IV 5 countries RIBOCICLIB
Study of efficacy, safety and tolerability of ianalumab versus placebo, in combination with SoC therapy, in participants with active lupus n… Ended

2023-508559-37-00 Phase III 9 countries IANALUMAB
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509345-12-00 Phase III 13 countries REMIBRUTINIB
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblasto… Ended

2023-506719-17-00 Phase I (Other) 3 countries
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509372-41-00 Phase III 15 countries REMIBRUTINIB
A research study to find out if the study treatment alpelisib (BYL719) is safe for a long period of time for who has confirmed diagnosis of … Ended

2023-508522-95-00 Phase II 3 countries ALPELISIB
Phase I study of IAG933 in patients with advanced Mesothelioma and other solid tumors Ended

2023-508369-34-00 Phase I 5 countries
A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cance… Ended

2023-509133-39-00 Phase III 16 countries
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Phase III 24 countries
Long-term safety and tolerability of iptacopan in patients with Paroxysmal Nocturnal Hemoglobinuria Ended

2023-509843-28-00 Phase III 7 countries IPTACOPAN
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Ended

2023-508838-33-00 Phase III 15 countries
A rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with prim… Ended

2023-508690-92-00 Phase III/IV 13 countries IPTACOPAN
PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therap… Ended

2023-507772-50-00 Phase III 9 countries GOZETOTIDE; LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN
Rollover Study for Patients with Sickle Cell Disease who have Completed a prior Novartis-Sponsored Crizanlizumab Study Ended

2024-510734-41-00 Phase IV 5 countries CRIZANLIZUMAB

Showing 121–144 of 224 trials

← All sponsors A–Z